Celgene Corporation (CELG)

Celgene Corp. (CELG) is a fully integrated biotechnology company focused on discovery, development and commercialization of drugs in the area of cancer and immune/inflammatory diseases.

The acquisition of Pharmion brings three medically meaningful products -- Thalomid, Revlimid and Vidaza -- into market, which will drive growth in 2009 and beyond. The myelodysplastic syndrome (MDS) market will be dominated by Celgene with complementary Vidaza and Revlimid, although Revlimid and Thalomid face tough competition in the multiple myeloma (MM) market.

Also, its strong balance sheet and deep pipeline will provide long-term growth for the company. Our price target is $70.

Celgene Corporation (CELG) : FULL ANALYST REPORT

Read the full analyst report on CELG